ATE511400T1 - Nukleinsäure-fomulierungen zur genverabreichung - Google Patents

Nukleinsäure-fomulierungen zur genverabreichung

Info

Publication number
ATE511400T1
ATE511400T1 AT01918339T AT01918339T ATE511400T1 AT E511400 T1 ATE511400 T1 AT E511400T1 AT 01918339 T AT01918339 T AT 01918339T AT 01918339 T AT01918339 T AT 01918339T AT E511400 T1 ATE511400 T1 AT E511400T1
Authority
AT
Austria
Prior art keywords
poly
acid
nucleic acid
acid formulations
gene administration
Prior art date
Application number
AT01918339T
Other languages
German (de)
English (en)
Inventor
Jason Fewell
Fiona Maclaughlin
Louis Smith
Francois Nicol
Alain Rolland
Original Assignee
Genetronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetronics Inc filed Critical Genetronics Inc
Application granted granted Critical
Publication of ATE511400T1 publication Critical patent/ATE511400T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01918339T 2000-03-03 2001-03-02 Nukleinsäure-fomulierungen zur genverabreichung ATE511400T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18723600P 2000-03-03 2000-03-03
US26175101P 2001-01-16 2001-01-16
PCT/US2001/006953 WO2001066149A2 (en) 2000-03-03 2001-03-02 Nucleic acid formulations for gene delivery and methods of use

Publications (1)

Publication Number Publication Date
ATE511400T1 true ATE511400T1 (de) 2011-06-15

Family

ID=26882847

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01918339T ATE511400T1 (de) 2000-03-03 2001-03-02 Nukleinsäure-fomulierungen zur genverabreichung

Country Status (9)

Country Link
US (2) US7173116B2 (enExample)
EP (1) EP1259265B1 (enExample)
JP (1) JP4987205B2 (enExample)
AT (1) ATE511400T1 (enExample)
AU (1) AU2001245427A1 (enExample)
BR (1) BR0108962A (enExample)
CA (1) CA2401327C (enExample)
DK (1) DK1259265T3 (enExample)
WO (1) WO2001066149A2 (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551996B1 (en) * 1999-07-26 2003-04-22 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
ATE428790T1 (de) 2000-09-25 2009-05-15 Genetronics Inc Verbessertes system zur regulation der transgenexpression
ATE536100T1 (de) 2001-10-26 2011-12-15 Baylor College Medicine Zusammensetzung für die änderung der knocheneigenschaften bei einem probanden
WO2003059382A2 (en) * 2001-12-28 2003-07-24 Supratek Pharma Inc. Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
EP1513559A4 (en) * 2002-05-28 2006-01-18 Advisys Inc INCREASED DELIVERY OF A NUCLEIC ACID CONSTRUCTION IN VIVO WITH THE POLY-L-GLUTAMATE (PLG) SYSTEM
US20080269153A1 (en) * 2002-05-28 2008-10-30 Ruxandra Draghia-Akli Increased stability of a dna formulation by including poly-l-glutamate
US20040014645A1 (en) * 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7316925B2 (en) 2002-07-16 2008-01-08 Vgx Pharmaceuticals, Inc. Codon optimized synthetic plasmids
AU2003302337A1 (en) * 2002-12-31 2004-07-29 The Johns Hopkins University Wound healing method and kits
US20040204358A1 (en) * 2003-01-28 2004-10-14 Advisys, Inc. Reducing culling in herd animals growth hormone releasing hormone (GHRH)
WO2004081167A2 (en) * 2003-03-11 2004-09-23 Applied Research Systems Ars Holding N.V. Expression vectors comprising the mcmv ie2 promoter
CA2521979A1 (en) * 2003-04-09 2004-10-28 University Of Utah Research Foundation Compositions and methods related to production of erythropoietin
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US20090005333A1 (en) * 2004-01-26 2009-01-01 Vgx Pharmaceuticlas, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
ES2436741T3 (es) * 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US20060094023A1 (en) * 2004-11-02 2006-05-04 Industrial Technology Research Institute Method for isolating nucleic acid by using amino surfactants
TWI294460B (en) * 2004-12-23 2008-03-11 Ind Tech Res Inst Method for stabilizing nucleic acids
CN101370927A (zh) * 2005-12-07 2009-02-18 基因特伦尼克斯公司 可变容积电穿孔室以及其方法
WO2007103070A2 (en) * 2006-03-03 2007-09-13 Genetronics, Inc. Method and device for treating microscopic residual tumors remaining in tissues following surgical resection
EP2094086B1 (en) 2006-11-08 2013-08-28 Veritas Bio, LLC In vivo delivery of double stranded rna to a target cell
FR2941152B1 (fr) * 2009-01-20 2013-10-18 Centre Nat Rech Scient Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
WO2012018594A2 (en) * 2010-07-26 2012-02-09 Scott & White Healthcare Plant-derived polysaccharides for delivery of rna-based therapies
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR101955365B1 (ko) 2011-07-12 2019-03-07 필라델피아 헬스 앤드 에듀케이션 코포레이션 디/비/에이 드렉셀 유니버시티 컬리지 오브 메디슨 신규한 클로스트리듐 디피실(Clostridium Difficile) DNA 백신
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
ES2816450T3 (es) 2012-02-22 2021-04-05 Univ Pennsylvania Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
ES2959443T3 (es) 2012-02-22 2024-02-26 Univ Pennsylvania Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2876730A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
JP6395711B2 (ja) * 2012-10-08 2018-09-26 リポカリクス・ゲーエムベーハー 形質導入試薬としてのカルボキシル化ポリアミン誘導体
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
DK3889173T5 (da) 2013-02-15 2024-08-05 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
CA2966035A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding t cells
HK1243333A1 (zh) 2014-10-31 2018-07-13 The Trustees Of The University Of Pennsylvania 用於修饰的t细胞的方法和组合物
KR20170075013A (ko) 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US10828353B2 (en) 2015-01-31 2020-11-10 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
EP3288580A4 (en) 2015-05-01 2018-12-26 The Regents of The University of California Glycan-dependent immunotherapeutic molecules
US11649435B2 (en) 2015-08-28 2023-05-16 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
AU2018246143B2 (en) 2017-03-28 2025-06-05 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
EP3684399A1 (en) 2017-12-29 2020-07-29 Cellectis Method for improving production of car t cells
CN118325840A (zh) 2018-03-27 2024-07-12 宾夕法尼亚大学董事会 具有增强功能的修饰的免疫细胞及其筛选方法
EP3793590A4 (en) 2018-05-17 2022-02-16 Regents of the University of Minnesota DRUG RESISTANT IMMUNE CELLS AND METHODS OF USE THEREOF
WO2020037142A1 (en) 2018-08-17 2020-02-20 Yale University Compositions and methods for high-throughput activation screening to boost t cell effector function
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
JP7654557B2 (ja) 2019-03-27 2025-04-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
WO2021108050A2 (en) 2019-10-23 2021-06-03 Yale University Compositions and methods comprising viral vector systems for multiplexed activation of endogenous genes as immunotherapy and viral-based immune-gene therapy
JP2023516080A (ja) 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
WO2021191871A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
US20230372484A1 (en) 2020-09-14 2023-11-23 Vor Biopharma Inc. Chimeric antigen receptors for treatment of cancer
EP4240405A1 (en) 2020-11-05 2023-09-13 Mendus B.V. Use of tumor-independent antigens in immunotherapies
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
KR20240107093A (ko) 2021-08-05 2024-07-08 고 테라퓨틱스, 인크. 항-글리코-muc4 항체 및 그의 용도
US20250066498A1 (en) 2021-09-03 2025-02-27 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
JP2024536722A (ja) 2021-09-03 2024-10-08 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｍｅｔ抗体およびその使用
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
CN119925619A (zh) * 2024-12-31 2025-05-06 首都医科大学 一种递送外源质粒dna的赋形剂及其制备和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543252A (en) * 1982-01-21 1985-09-24 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
EP0150184A1 (fr) 1983-07-01 1985-08-07 Battelle Memorial Institute Polypeptide biodegradable et son utilisation pour le relargage progressif de medicaments
DE3581471D1 (de) 1984-10-19 1991-02-28 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
JP3368603B2 (ja) 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
EP0695186A1 (en) 1993-04-28 1996-02-07 Ribozyme Pharmaceuticals, Inc. Ocular delivery of nucleic acid
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
US6271205B1 (en) * 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
FR2732218B1 (fr) 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
FR2766706B1 (fr) 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
US6040925A (en) 1997-12-12 2000-03-21 Hewlett-Packard Company Radial and pruned radial interpolation
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
US6697669B2 (en) * 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US7396919B1 (en) * 1998-07-17 2008-07-08 Mirus Bio Corporation Charge reversal of polyion complexes
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
AU5376500A (en) 1999-06-17 2001-01-09 Universiteit Gent Functional poly-alpha-aminoacid derivatives useful for the modification of biologically active materials and their application
AU5624500A (en) 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid microspheres for sustained gene transfer
WO2001013723A1 (en) 1999-08-20 2001-03-01 Mirus Corporation Charge reversal of polyion complexes
BR0108959A (pt) * 2000-03-03 2003-10-14 Valentis Inc Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
ATE428790T1 (de) * 2000-09-25 2009-05-15 Genetronics Inc Verbessertes system zur regulation der transgenexpression

Also Published As

Publication number Publication date
BR0108962A (pt) 2002-12-24
US7173116B2 (en) 2007-02-06
EP1259265B1 (en) 2011-06-01
JP2003525912A (ja) 2003-09-02
US20070213287A1 (en) 2007-09-13
DK1259265T3 (da) 2011-07-11
CA2401327A1 (en) 2001-09-13
WO2001066149A2 (en) 2001-09-13
WO2001066149A3 (en) 2002-03-14
US20030109478A1 (en) 2003-06-12
US7491537B2 (en) 2009-02-17
CA2401327C (en) 2014-05-06
AU2001245427A1 (en) 2001-09-17
EP1259265A2 (en) 2002-11-27
JP4987205B2 (ja) 2012-07-25

Similar Documents

Publication Publication Date Title
ATE511400T1 (de) Nukleinsäure-fomulierungen zur genverabreichung
PT1404300E (pt) Composições farmacêuticas de dispersões de fármacos e polímeros neutros
ZA200206723B (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof.
DE60142616D1 (de) Hydrogelzusammensetzung zur transdermalen arzneistoffabgabe
AP2002002558A0 (en) Pharmaceutical compositions containing polymer and drug assemblies.
AU3085102A (en) Drug delivery compositions and medical devices containing block copolymer
AU2002301098A1 (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof
DE69909519D1 (de) Biologisch abbaubare ph/thermosensitive hydrogele zur verzörgerten freisetzung biologisch aktiver stoffe
BR0212475A (pt) Composições farmacêuticas
FR2829387B1 (fr) Compositions cosmetiques contenant un copolymere d'acide methacrylique, une dimethicone et un polymere cationique et leurs utilisations
AU2002300821A1 (en) Cosmetic compositions containing a methacrylic acid copolymer, a silicone and a cationic polymer, and uses thereof
ATE493114T1 (de) Mucoadhäsive zusammensetzung zur verabreichung von biologisch aktiven substanzen in tiergewebe
GB0317999D0 (en) Improvements in or relating to drug delivery systems
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
ATE426397T1 (de) Copolymer-zusammensetzungen zur oralen verabreichung
MXPA03004828A (es) Composiciones de poliomeros de dispersion liquida, su preparacion y su uso.
FR2819179B1 (fr) Compositions photoprotectrices a base de polymeres amphiphiles
AU2357202A (en) Ion-strength independent sustained release pharmaceutical formulation
DE60116359D1 (de) Kahalalid f formulierung
FR2829384B1 (fr) Compositions cosmetiques contenant un copolymere d'acide methacrylique, une silicone et un polymere cationique et leurs utilisations
FR2829386B1 (fr) Compositions cosmetiques contenant un copolymere d'acide methacrylique, une dimethicone, un agent nacrant et un polymere cationique et leurs utilisations
HN2003000115A (es) Formulacion farmaceutica que comprende melatonina
SE0001916D0 (sv) Novel formulation
AU4764600A (en) Water dispersible polyamides with ethylenically unsaturated ends
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties